X0306 4 2015-04-01 1 0001009356 SALIX PHARMACEUTICALS LTD SLXP 0001291937 Bertrand William C JR 8510 COLONNADE CENTER DRIVE RALEIGH NC 27615 0 1 0 0 See Remarks Common Stock 2015-04-01 4 U 0 2969 173 D 0 D Common Stock 2015-04-01 4 D 0 28289 173 D 0 D Shares tendered for an offer price of $173.00 per share in cash, subject to any applicable withholding taxes, pursuant to the tender offer consummated on April 1, 2015 pursuant to the terms of the Agreement and Plan of Merger, dated as of February 20, 2015 (as amended, the "Merger Agreement"), by and among the Issuer, Valeant Pharmaceuticals International ("VPI"), a Delaware corporation and a wholly owned subsidiary of Valeant, Sun Merger Sub, Inc. ("Merger Sub"), a Delaware corporation and a wholly owned subsidiary of VPI, and solely for purposes of guaranteeing VPI's and Merger Sub's obligations under the Merger Agreement, Valeant Pharmaceuticals International, Inc. ("Valeant"), a British Columbia corporation. Pursuant to the terms of the Merger Agreement, on April 1, 2015, each share of the Issuer's restricted stock issued and outstanding immediately prior to the Effective Time (as defined in the Merger Agreement) was converted into the right to receive $173.00 per share in cash, subject to any applicable withholding taxes. Executive Vice President, General Counsel and Acting Chief Operating Officer /s/ William C. Bertrand Jr. 2015-04-03